-
Mashup Score: 48Second-Line Belantamab Mafodotin in Multiple Myeloma: Will These DREAMMs Become Reality? - 1 day(s) ago
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this article, the authors describe how they expect belantamab mafodotin to be used and how the drug’s ocular toxicities may be managed if the drug regains regulatory approval.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 48Second-Line Belantamab Mafodotin in Multiple Myeloma: Will These DREAMMs Become Reality? - 2 day(s) ago
Belantamab mafodotin, an antibody-drug conjugate targeting BCMA in multiple myeloma, is likely to regain FDA approval based on the DREAMM-7 and DREAMM-8 trials. In this article, the authors describe how they expect belantamab mafodotin to be used and how the drug’s ocular toxicities may be managed if the drug regains regulatory approval.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Thanks @ASCO Daily News for taking a chance on this paper from #dorishansen & me 🙏🏽 When belantamab gets re-approved (already re-approved in 🇬🇧) for #MMsm, how might MDs dose it to maximize efficacy & safety? Our Bela-Vd and Bela-Pd suggestions ⬇️ https://t.co/sTuZx9fem0 https://t.co/Csiqdu7QTQ
-
-
Mashup Score: 13ASCO-SNO Guideline Update Addresses Use of Vorasidenib for Astrocytic and Oligodendroglial Tumors - 2 day(s) ago
ASCO and Society of Neuro-Oncology have released a rapid recommendation update to their joint guideline, addressing the use of vorasidenib in selected patients with grade 2 astrocytomas or oligodendrogliomas with a susceptible IDH1 or IDH2 mutation. The update is based on results of the phase 3 INDIGO trial, which showed that vorasidenib was associated with a significant improvement in PFS and a delay in the time to next intervention compared with placebo among this patient population.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
This week's update to our joint guideline w/ @NeuroOnc addresses using vorasidenib in selected pts w/ grade 2 astrocytomas or oligodendrogliomas w/ a susceptible IDH1/IDH2 mutation. #ASCODailyNews has more, including interviews with guideline co-chairs: https://t.co/gvktW4Wobf https://t.co/dHJq33FaKz
-
-
Mashup Score: 18
Results from the multisite PRO-TECT trial show that using electronic patient-reported outcomes symptom monitoring has positive effects for patients receiving outpatient treatment with palliative intent for advanced or metastatic cancer.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Did you know ePROs can improve patient care & provider workflows? A new study dives into the benefits & challenges of these systems. Read more on @ASCODailyNews: https://t.co/sCXDD7RQIv https://t.co/RJzmSRts6y
-
-
Mashup Score: 2Harnessing the Immune System to Its Full Potential: Immunologic Approaches to Multiple Myeloma Management - 10 day(s) ago
An Education Session at the 2025 ASCO Annual Meeting will explore current and future opportunities for immunotherapy—including quadruplet regimens and bispecific T-cell engagers—in newly diagnosed multiple myeloma.
Source: dailynews.ascopubs.orgCategories: General Medicine NewsTweet-
Thank you @ASCO daily news for covering what we will discuss along with my colleagues: @JayaniReena and @suvannasankha Harnessing the Immune System to Its Full Potential: Immunologic Approaches to Multiple Myeloma Management @UAMSMyeloma https://t.co/onbBFoYX73 Looking for
-
-
Mashup Score: 9
Dr. John Sweetenham, Dr. Larry Shulman, and Dr. Rebecca Maniago discuss the integration of clinical pathways and decision support tools into the cancer center workflow, challenges to implementation at the point of care, and the promise of AI to further unlock these tools for clinicians.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
On the latest episode of the ASCO Daily News Podcast, find out why it can be difficult for oncologists to integrate oncology clinical pathways into their workflow and how technological advances like AI can help: https://t.co/60GOVsrm5z https://t.co/wwPzYdEePg
-
-
Mashup Score: 17Appendix Cancer Is Not the Same as Colorectal Cancer: Implications for Systemic Chemotherapy - 15 day(s) ago
Historically, medical oncologists have treated patients with appendiceal adenocarcinoma with the same chemotherapy that would be used for patients with colorectal cancer, despite these diseases exhibiting strikingly different tumor identities and natural disease courses. Growing recognition that appendix cancer is a unique disease entity and an unmet oncologic need is increasing research investment in this orphan disease.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
ICYMI: @jpshen_md of @MDAndersonNews and @MikeFooteMD of @MSKCancerCenter discuss how appendix cancer differs from CRC and examine new potential targeted treatments: https://t.co/mO0HUidwSE #ASCODailyNews https://t.co/vcq5dyIRBS
-
-
Mashup Score: 13ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer - 15 day(s) ago
A new ASCO clinical practice guideline update recommends that sentinel lymph node biopsy and axillary lymph node dissection be omitted from the treatment of select patients with early-stage breast cancer.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
For more on this new guideline, read in-depth analysis from #ASCODailyNews w/ commentary from Expert Panel co-chairs @MylinTorres of @WinshipAtEmory & @KClaraPark of @Brighamsurgery @DanaFarber: https://t.co/rezDSfX1tg https://t.co/xpIwcWm1cx https://t.co/wn4eBXKMCu
-
-
Mashup Score: 5De-escalating Treatment in De Novo Oligometastatic Prostate Cancer: Which Patients Benefit? - 18 day(s) ago
Small studies in prostate cancer suggest that intermittent androgen deprivation therapy (ADT) or treatment breaks may be a viable option for select patients with sustained remission and no radiographic evidence of disease. Ongoing clinical trials are investigating strategies to balance the benefits of ADT in controlling prostate cancer with the need to mitigate treatment-related adverse effects and improve patient quality of life.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
ICYMI: Small studies in prostate cancer suggest that intermittent androgen deprivation therapy or treatment breaks may be an option for certain patients. @jordanciuro, @bilenma & Dr. Shahid Ahmed discuss de-escalation decisions for #ASCODailyNews: https://t.co/uY2roGb35O https://t.co/Xgtqtss80k
-
-
Mashup Score: 7Using Combination PARP Inhibitor and Androgen Receptor Pathway Inhibitor Treatment for Patients With BRCA1/2-Mutated Metastatic Prostate Cancer - 24 day(s) ago
Combination PARP inhibitor and androgen receptor pathway inhibitor treatment benefits patients with metastatic castration-resistant prostate cancer with specific homologous recombination repair gene mutations, especially BRCA1/2 mutations. The BRCAAway study highlighted the advantage of this combination therapy over monotherapy approaches; one explanation for this benefit may be the suppression of multiple divergent-resistant tumor clonal pathways.
Source: dailynews.ascopubs.orgCategories: General Medicine NewsTweet-
RT @JVentoMD: Our @ASCO update on PARPi+ARPI therapy in BRCA-mut mHRPC: https://t.co/BDeG7vzmOE @TiansterZhang Why diff in combo vs seq c…
-
Thanks @ASCO Daily News for taking a chance on this paper from #dorishansen & me 🙏🏽 When belantamab gets re-approved (already re-approved in 🇬🇧) for #MMsm, how might MDs dose it to maximize efficacy & safety? Our Bela-Vd and Bela-Pd suggestions ⬇️ https://t.co/sTuZx9fem0 https://t.co/Csiqdu7QTQ